Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc-by-nc (c) Rodríguez, Dolores et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/190158

Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Aim: Vaccination against SARS-CoV2 has been proposed as a fundamental element for the control of the pandemic. This study aimed to describe the suspected adverse reactions (ADR) reported by vaccinated hospital workers. Methods: A descriptive study of suspected ADR was conducted between January and March 2021. The suspected ADR were identified using a specifically designed electronic form and spontaneous reporting. Data were also collected regarding the characteristics of the professionals, vaccine administered, severity, and outcome of ADR. Results: 8169 professionals received 2 doses of SARS-CoV2 vaccine (6672 Comirnaty (R) and 1497 Spikevax (R)) and 894 reports of suspected ADR were reported (762 for Comirnaty (R) and 132 for Spikevax (R)), resulting in a cumulative ADR incidence of 10.94% (95%CI: 10.27-11.62). The majority of ADR were reported only after the second dose, 497 (56.2%), while 211 (23.6%) were reported only after the first dose and 186 (21%) after both doses. The symptoms were mostly mild, did not require medical assistance, and disappeared within approximately 3 days. One hundred and seventeen professionals had a history of COVID-19 infection. These studies reported, statistically significant, more suspected ADR after the first dose (42.7%) than those with no history of COVID-19 (20.7%). Among professionals, more ADR occurred after the first dose with the Spikevax (R) vaccine (41.6%) than with the Comirnaty (R) vaccine (20.5%). Conclusion: The majority of suspected ADR reported were described in the summary of product characteristics (SmPC). Professionals with a history of COVID-19 reported more suspected ADR after the first dose than did those without a history.

Subject (English)

Citation

Citation

RODRÍGUEZ, Dolores, et al. Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study. Medicine. 2022. Vol. 101, num. 41, pags. e30976. ISSN 1536-5964. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/190158

Export metadata

JSON - METS

Share record